Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 8/20 | 0.45 |
| ▸ | PPARA | Q07869 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | FBP1 | P09467 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2532462 | 1.00 | FASN (0.51) | FASNPPARGPPARAALDH1A1TSHR | |
| SCHEMBL2533250 | 1.00 | FASN (0.51) | FASNPPARGPPARAALDH1A1TSHR | |
| SCHEMBL16038842 | 1.00 | FASN (0.51) | FASNPPARGPPARAALDH1A1TSHR | |
| SCHEMBL16038846 | 1.00 | FASN (0.51) | FASNPPARGPPARAALDH1A1TSHR | |
| SCHEMBL2533246 | 1.00 | FASN (0.51) | FASNPPARGPPARAALDH1A1TSHR | |
| SCHEMBL6369891 | 0.78 | PPARG (0.58) | PPARGPPARAFAAHTRPA1FBP1 | |
| SCHEMBL1055870 | 0.78 | FASN (0.61) | FASNPPARGPPARAALDH1A1TSHR | |
| SCHEMBL2732862 | 0.78 | FASN (0.61) | FASNPPARGPPARAALDH1A1TSHR | |
| SCHEMBL1039992 | 0.78 | FASN (0.61) | FASNPPARGPPARAALDH1A1TSHR | |
| SCHEMBL21925330 | 0.78 | PPARG (0.58) | PPARGPPARAFAAHTRPA1FBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025064491-A1 | METHODS FOR FAT REDUCTION | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2025-03-27 | — | — | WO | claimed |
| US-9308189-B2 | Nitro fatty acids—neuroprotection and/or inhibition of cognitive decline | NITROMEGA CORP. (US) | 2016-04-12 | — | — | US | claimed |
| CN-102843922-B | The neuroprotective of Xiao base Zhi Fang Suan – cognitive decline and/or suppression | NITROMEGA CORP. (US) | 2015-12-16 | — | — | CN | claimed |
| CN-104288138-A | Nutraceuticals containing nitro fatty acids | NITROMEGA CORP | 2015-01-21 | — | — | CN | claimed |
| US-20140271844-A1 | COMPOSITIONS CONTAINING NITRO FATTY ACIDS | COMPLEXA, INC. | 2014-09-18 | — | — | US | claimed |
| EP-2726086-A2 | COMPOSITIONS CONTAINING NITRO FATTY ACIDS | Nitromega Corp. (US) | 2014-05-07 | — | — | EP | claimed |
| US-20140017219-A1 | NITRO FATTY ACIDS - NEUROPROTECTION AND/OR INHIBITION OF COGNITIVE DECLINE | NITROMEGA CORP. (US) | 2014-01-16 | — | — | US | claimed |
| US-8563609-B2 | Nitro fatty acids - neuroprotection and/or inhibition of cognitive decline | NITROMEGA CORP. (US) | 2013-10-22 | — | — | US | claimed |
| WO-2013003689-A2 | COMPOSITIONS CONTAINING NITRO FATTY ACIDS | NITROMEGA CORP. (US) | 2013-01-03 | — | — | WO | claimed |
| CN-102843922-A | Nitro fatty acids - neuroprotection and/or inhibition of cognitive decline | NITROMEGA CORP | 2012-12-26 | — | — | CN | claimed |
| CN-102307464-A | Nutrition product containing nitro fatty acid | NITROMEGA CORP | 2012-01-04 | — | — | CN | claimed |
| US-20110280852-A1 | NITRO FATTY ACIDS - NEUROPROTECTION AND/OR INHIBITION OF COGNITIVE DECLINE | NITROMEGA CORP. (US) | 2011-11-17 | — | — | US | claimed |
| US-20100166918-A1 | NUTRACEUTICALS CONTAINING NITRO FATTY ACIDS | COMPLEXA, INC. | 2010-07-01 | — | — | US | claimed |
| US-20160256508-A1 | COMPOSITIONS CONTAINING NITRO FATTY ACIDS | COMPLEXA, INC. | 2016-09-08 | — | — | US | disclosed |
| US-9308189-B2 | Nitro fatty acids—neuroprotection and/or inhibition of cognitive decline | NITROMEGA CORP. (US) | 2016-04-12 | — | — | US | disclosed |
| CN-102843922-B | The neuroprotective of Xiao base Zhi Fang Suan – cognitive decline and/or suppression | NITROMEGA CORP. (US) | 2015-12-16 | — | — | CN | disclosed |
| EP-2384114-A1 | NUTRACEUTICALS CONTAINING NITRO FATTY ACIDS | Nitromega Corp. (US) | 2011-11-09 | — | — | EP | disclosed |
| US-20110256247-A1 | TOPICAL COMPOSITIONS CONTAINING NITRO FATTY ACIDS | NITROMEGA CORP. (US) | 2011-10-20 | — | — | US | disclosed |
| WO-2010078504-A1 | NUTRACEUTICALS CONTAINING NITRO FATTY ACIDS | NITROMEGA CORP. (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20100166918-A1 | NUTRACEUTICALS CONTAINING NITRO FATTY ACIDS | COMPLEXA, INC. | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140271844-A1 | COMPOSITIONS CONTAINING NITRO FATTY ACIDS | ALOX5, FASN, ALOX12 | FASN 2/4885PPARG 26/4885PPARA 58/4885 |
| US-20110256247-A1 | TOPICAL COMPOSITIONS CONTAINING NITRO FATTY ACIDS | ALOX5, FASN, FPR1 | FASN 2/4885PPARG 25/4885PPARA 33/4885 |
| US-20140017219-A1 | NITRO FATTY ACIDS - NEUROPROTECTION AND/OR INHIBITION OF COGNITIVE DECLINE | NLN, SMN1; SMN2, ELOVL1 | FASN 22/4885PPARG 51/4885PPARA 73/4885 |
| US-20110280852-A1 | NITRO FATTY ACIDS - NEUROPROTECTION AND/OR INHIBITION OF COGNITIVE DECLINE | NLN, SMN1; SMN2, CASP10 | FASN 40/4885PPARG 88/4885PPARA 142/4885 |
| US-20160256508-A1 | COMPOSITIONS CONTAINING NITRO FATTY ACIDS | ALOX5, FASN, ALOX12 | FASN 2/4885PPARG 26/4885PPARA 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.